Table 1.
Patient Pretransplantation Characteristics
| Characteristic | Value |
| Number of patients | 45 |
| Age, yr, median (range) | 32 (15-63) |
| Age >50 yr, n (%) | 14 (31.1) |
| Males/females, n | 28/17 |
| Etiology of aplasia, n (%) | |
| Idiopathic | 41 (91.2) |
| Posthepatitic (seronegative) | 2 (4.4) |
| Eosinophilic fasciitis | 1 (2.2) |
| Celiac disease | 1 (2.2) |
| Type of donor, n (%) | |
| Matched sibling | 12 (26.6) |
| Unrelated | 33 (73.4) |
| 9/10 unrelated | 8 of 33 (24.2) |
| Previous immunosuppressive therapy, n/N (%) | |
| Matched sibling donor | 6/12 (50) |
| Unrelated donor | 27/33 (81.8); P = .055 |
| Time to transplantation, d, median (range) | |
| Matched sibling donor | 5.9 (2.7-34.7) |
| Unrelated donor | 8.4 (2.1-178.9); P = .095 |
| HLA alloimmunization, n (%) | 11 (24.4) |
| Stem cell source, n (%) | |
| Bone marrow | 7 (15.5) |
| Peripheral blood stem cells | 38 (84.5) |
| PNH clone, n (%) | 21 (46.6) |
| PNH clone size, % median (range) | |
| Granulocytes | 2 (0.02-40) |
| Monocytes | 2.85 (0.01-32) |
| Red cells | Not available |
| Alemtuzumab dose, mg, median (range) | 70 (45-100) |
| CD34+ stem cell dose, × 106/kg, median (range) | 6.55 (1.97-12.40) |
| Follow-up after HSCT, mo, median (range) | 31.4 (3-93) |
HSCT indicates hematopoietic stem cell transplantation; PNH, paroxysmal nocturnal hemoglobinuria.